These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29535738)

  • 1. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
    Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
    Front Immunol; 2018; 9():377. PubMed ID: 29535738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
    Li Z; Tang J; Sun L; Ye Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors.
    Bhat J; Oberg HH; Kabelitz D
    Cell Immunol; 2015 Jul; 296(1):50-6. PubMed ID: 25708484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
    Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
    Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
    Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
    Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
    Front Immunol; 2020; 11():1405. PubMed ID: 32793196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
    Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
    Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3β activation.
    Li S; Li JJ
    Neoplasma; 2019 Sep; 66(5):766-775. PubMed ID: 31288526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
    Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
    J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
    Li Z; Peng H; Xu Q; Ye Z
    J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
    Ko Y; Jeong YH; Lee JA
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
    Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
    Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
    Arkko S; Zlatev HP; Mönkkönen H; Räikkönen J; Benzaïd I; Clézardin P; Mönkkönen J; Määttä JA
    Cancer Lett; 2015 Feb; 357(1):279-285. PubMed ID: 25444923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin C promotes the proliferation and effector functions of human γδ T cells.
    Kouakanou L; Xu Y; Peters C; He J; Wu Y; Yin Z; Kabelitz D
    Cell Mol Immunol; 2020 May; 17(5):462-473. PubMed ID: 31171862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Izumi H; Yamasaki A; Takeda K; Kodani M; Touge H; Tanaka N; Yanai M; Ueda Y; Sakamoto T; Nishii-Ito S; Makino H; Yamaguchi K; Igishi T; Shimizu E
    Lung Cancer; 2018 Aug; 122():200-205. PubMed ID: 30032832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
    Fowler D; Barisa M; Southern A; Nattress C; Hawkins E; Vassalou E; Kanouta A; Counsell J; Rota E; Vlckova P; Draper B; De Mooij T; Farkas A; Brezovjakova H; Baker AT; Scotlandi K; Manara MC; Tape C; Chester K; Anderson J; Fisher J
    Sci Transl Med; 2024 May; 16(749):eadg9814. PubMed ID: 38809963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
    Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
    Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.